{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:03:26Z","timestamp":1793829806889,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jpba.2023.115594","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T11:22:24Z","timestamp":1689592944000},"page":"115594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Development and validation of an LC\u2013MS\/MS method to measure the BRAF inhibitors dabrafenib and encorafenib quantitatively and four major metabolites semi-quantitatively in human plasma"],"prefix":"10.1016","volume":"234","author":[{"given":"Melody F.","family":"Myszkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K.L.","family":"Goey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115594_bib1","unstructured":"S.M. Swetter, J.A. Thompson, M.R. Albertini, C.A. Barker, J. Baumgartner, G. Boland, B. Chmielowski, D. DiMaio, R.C. Fields, M.D. Fleming, A. Galan, B. Gastman, S. Guild, A. Holder, J. Hyngstrom, D. Johnson, R.W. Joseph, G. Karakousis, K. Kendra, M. Kiuru, J.R. Lange, R. Lanning, A.J. Olszanski, P.A. Ott, M.I. Ross, A.K. Salama, R. Sharma, J. Skitzki, J. Sosman, K. Tsai, Y. Xing, E. Wuthrick, N.R. McMillian, M. Nguyen, Cutaneous Melanoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf, (accessed 1 March 2023)."},{"issue":"10","key":"10.1016\/j.jpba.2023.115594_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jpba.2023.115594_bib3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9992","key":"10.1016\/j.jpba.2023.115594_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jpba.2023.115594_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jpba.2023.115594_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102463","article-title":"Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis","volume":"110","author":"Corrie","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jpba.2023.115594_bib7","series-title":"Systemic Treatment of Metastatic Melanoma with BRAF and Other Molecular Alterations","author":"Sosman","year":"2022"},{"key":"10.1016\/j.jpba.2023.115594_bib11","unstructured":"European Medicines Agency, Summary of Product Characteristics - dabrafenib (Tafinlar). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tafinlar-epar-product-information_en.pdf, 2023 (accessed 2 March 2023)."},{"issue":"3","key":"10.1016\/j.jpba.2023.115594_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-021-04299-x","article-title":"Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic\u2013pharmacodynamic real-life study","volume":"88","author":"Goldwirt","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"issue":"6","key":"10.1016\/j.jpba.2023.115594_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/jcph.263","article-title":"Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites","volume":"54","author":"Ouellet","year":"2014","journal-title":"J. Clin. Pharm."},{"issue":"4","key":"10.1016\/j.jpba.2023.115594_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur. J. Clin. Pharm."},{"issue":"10","key":"10.1016\/j.jpba.2023.115594_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jpba.2023.115594_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122752","article-title":"Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC\u2013MS\/MS in human plasma: application to therapeutic drug monitoring in patients with non-small cell lung cancer","volume":"1175","author":"Zhou","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115594_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113718","article-title":"Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry","volume":"193","author":"Balakirouchenane","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.jpba.2023.115594_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00216-020-03031-7","article-title":"Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma","volume":"413","author":"Aghai","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"issue":"3","key":"10.1016\/j.jpba.2023.115594_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4758","article-title":"Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC\u2013MS\/MS","volume":"34","author":"Krens","year":"2020","journal-title":"Biomed. Chromatogr."},{"issue":"4","key":"10.1016\/j.jpba.2023.115594_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-019-03780-y","article-title":"Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia","volume":"83","author":"Kim","year":"2019","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.jpba.2023.115594_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jchromb.2018.02.008","article-title":"Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry","volume":"1083","author":"Cardoso","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115594_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","article-title":"High throughput routine determination of 17 tyrosine kinase inhibitors by LC\u2013MS\/MS","volume":"150","author":"Merienne","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"10.1016\/j.jpba.2023.115594_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4147","article-title":"Development and validation of a liquid chromatography\u2013tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs","volume":"32","author":"Herbrink","year":"2018","journal-title":"Biomed. Chromatogr."},{"issue":"15","key":"10.1016\/j.jpba.2023.115594_bib26","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s00216-017-0316-8","article-title":"Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma","volume":"409","author":"Vikingsson","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2023.115594_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cca.2017.04.009","article-title":"An UPLC\u2013MS\/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients","volume":"470","author":"Rousset","year":"2017","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.jpba.2023.115594_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FTD.0000000000000357","article-title":"Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC\u2013MS\/MS","volume":"39","author":"Huynh","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2023.115594_bib29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jchromb.2016.09.012","article-title":"Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma","volume":"1033\u20131034","author":"Sparidans","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"12","key":"10.1016\/j.jpba.2023.115594_bib30","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1124\/dmd.113.053785","article-title":"Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation","volume":"41","author":"Bershas","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.jpba.2023.115594_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1081\/JLC-100101455","article-title":"Bioanalytical liquid chromatographic method validation. A review of current practices and procedures","volume":"23","author":"Rosing","year":"2000","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2023.115594_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijms.2021.116559","article-title":"Interpretation of MS\u2013MS spectra of small-molecule signal transduction inhibitors using accurate-m\/z data and m\/z-shifts with stable-isotope-labeled analogues and metabolites","volume":"464","author":"Niessen","year":"2021","journal-title":"Int. J. Mass Spectrom."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523003631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523003631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:35:47Z","timestamp":1760002547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523003631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":27,"alternative-id":["S0731708523003631"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115594","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an LC\u2013MS\/MS method to measure the BRAF inhibitors dabrafenib and encorafenib quantitatively and four major metabolites semi-quantitatively in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115594"}}